Biome Australia Limited (ASX:BIO) Reports First Net Profit and Unveils Vision 27 Strategic Plan
Biome Australia (ASX:BIO) reports its first net profit in H1 FY25 and launches Vision 27 strategic plan with $75-$85m revenue guidance.
Category: Healthcare
Biome Australia Limited (ASX:BIO) Announces Half-year Results
Biome Australia Limited (ASX:BIO) reports a 47% revenue increase and a net profit of $433k for the half-year ended 31 December 2024.
Althea Group Holdings (ASX:AGH) Secures $4.0M for North America THC Beverage Expansion
Althea Group Holdings (ASX:AGH) raises $4.0 million to expand THC beverage production in North America.
Neurizon Therapeutics Limited (ASX:NUZ) Receives FDA Guidance on NUZ-001 IND Application
Neurizon Therapeutics Limited (ASX:NUZ) receives FDA guidance on its IND application for NUZ-001, requesting additional animal exposure data.
Recce Pharmaceuticals (ASX:RCE) Reports Successful Phase II Trial Results
Recce Pharmaceuticals (ASX:RCE) reports successful Phase II trial of RECCE®327 Gel, advancing to Phase III for ABSSSI treatment.
The Calmer Co International Limited (ASX:CCO) Secures $2.6m FJD Loan for Navua Facility Acquisition
The Calmer Co (ASX:CCO) secures a $2.6m FJD loan for acquiring its Navua facility, enhancing its operational capabilities.
Avecho Biotechnology Limited (ASX:AVE) Addresses Recent Securities Trading
Avecho Biotechnology Limited (ASX:AVE) addresses recent securities trading, citing potential Phase III trial success and confirms compliance with ASX listing rules.
Wellnex Life Limited (ASX:WNX) Announces A$9 Million Commitments for AIM Dual Listing
Wellnex Life Limited (ASX:WNX) secures A$9 million in commitments for its AIM dual listing, enabling significant cost savings and supporting future growth.
Artrya Limited (ASX:AYA) Successfully Completes A$15 Million Placement
Artrya Limited (ASX:AYA) secures A$15 million through a two-tranche placement to advance its Salix® AI platform’s regulatory and commercial initiatives.
Imugene Limited (ASX:IMU) Reports 57% Complete Response Rate in CAR-T Trial
Imugene Limited (ASX:IMU) reports a 57% complete response rate in its Phase 1b CAR-T trial for relapsed/refractory DLBCL.